Compare ProShares Ultra Silver ETF (AGQ) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra Silver ETF vs Amphastar Pharmaceuticals Inc — how do they compare? ProShares Ultra Silver ETF trades at $79.45, while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, ProShares Ultra Silver ETF nearer its low. Which is the better fit depends on your goals.
| AGQ | AMPH | |
|---|---|---|
Sector | Leveraged / Inverse | Health |
52-Week High | $400.47 | $30.81 |
52-Week Low | $49.73 | $16.87 |
Market Cap | — | $863.95M |
Enterprise Value | — | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ProShares Ultra Silver (AGQ) is trading at $76.86, up 5.97% on strong silver price momentum. The technical picture shows bullish moving averages with RSI indicating potential overbought conditions near resistance at $78. Recent news highlights AGQ's 9.39% surge as silver rallied 4-5%, though structural decay concerns persist for this 2x leveraged ETF.
The outlook remains volatile with silver price movements driving performance. Investment opportunity exists for bullish silver investors seeking amplified exposure, but structural decay and beta slippage present significant risks. AGQ consistently underperforms unlevered silver ETFs over time, making it suitable only for short-term tactical positions.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ProShares Ultra Silver ETF
AGQ is a leveraged ETF that seeks daily investment results corresponding to two times (2x) the daily performance of silver bullion. It is designed for investors seeking magnified short-term exposure to silver prices.
Read more on AGQ →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
